Combined modality therapy for small cell lung cancer patient with limited stage disease / 中华肿瘤杂志
Chinese Journal of Oncology
;
(12): 701-703, 2007.
Article
Dans Chinois
| WPRIM
| ID: wpr-298514
ABSTRACT
<p><b>OBJECTIVE</b>To investigate the efficacy of combined modality therapy for small cell lung cancer (SCLC) patient with limited stage disease (LD).</p><p><b>METHODS</b>The data of 122 SCLC patients with limited stage disease treated by surgery combined with chemotherapy and radiotherapy were analysed retrospectively.</p><p><b>RESULTS</b>The median survival time (MST) of the 122 patients was 38 months, the 1-, 3-, 5-year survival rate was 83.6%, 50.0% and 38.0%, respectively. If stratified the patients by TNM stage, the MST of stage I was not reached yet, it was 52 months for stage II and 22 months for stage III (P = 0.001); the 5-year survival rate was 57.1%, 43.1% and 28.3%, respectively. For stage III, the MST and 5-year survival rate was 40 months and 45.3% for the patients who received postoperative chemoradiotherapy, and only 20 months and 26.1% for those who were treated with postoperative chemotherapy alone (P = 0.071).</p><p><b>CONCLUSION</b>Combined modality therapy can improve the survival of small cell lung cancer patient with limited stage disease, and TNM stage is still a significant prognostic factor.</p>
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Anatomopathologie
/
Pneumonectomie
/
Thérapeutique
/
Protocoles de polychimiothérapie antinéoplasique
/
Taux de survie
/
Études rétrospectives
/
Études de suivi
/
Traitement médicamenteux adjuvant
/
Radiothérapie adjuvante
/
Utilisations thérapeutiques
Type d'étude:
Étude observationnelle
/
Étude pronostique
/
Facteurs de risque
Limites du sujet:
Adulte
/
Adulte très âgé
/
Aged80
/
Femelle
/
Humains
/
Mâle
langue:
Chinois
Texte intégral:
Chinese Journal of Oncology
Année:
2007
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS